Research graph
References from Genomic and clinical determinants of response to Azacitidine plus venetoclax in acute myeloid leukemia: Results from the HM-SCREEN-Japan 02 study. Local targets link to admitted publications; unresolved targets remain external evidence.
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia
10.1200/jco.2009.23.8329 · 2010 · External reference
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
10.1182/blood-2015-01-621664 · 2015 · External reference
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
10.1016/j.ccr.2006.10.006 · 2006 · External reference
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
10.1056/nejmoa2012971 · 2020 · External reference
Inhibition of amino acid metabolism selectively targets human leukemia stem cells
10.1016/j.ccell.2018.10.005 · 2018 · External reference
Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia
10.1038/s41591-018-0233-1 · 2018 · External reference
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
10.1182/bloodadvances.2021005538 · 2021 · External reference
Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax + azacitidine versus intensive chemotherapy
External reference
Dynamics of clonal evolution in myelodysplastic syndromes
10.1038/ng.3742 · 2017 · External reference
Multi-gene measurable residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine
10.3324/haematol.2023.283790 · 2024 · External reference
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
10.1182/blood-2016-03-643544 · 2016 · External reference
A practice-oriented genome-profiling study for acute myeloid leukemia using the novel HANDLE system: HM-screen-JAPAN02
10.1007/s12185-024-03895-w · 2025 · External reference
Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach
10.2307/2531595 · 1988 · External reference
Investigation of the freely available easy-to-use software “EZR” for medical statistics
10.1038/bmt.2012.244 · 2013 · External reference
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
10.1182/blood.2022016867 · 2022 · External reference
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
10.1182/blood.2024025409 · 2024 · External reference
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
10.1182/blood.2024024944 · 2024 · External reference
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
10.1016/s1470-2045(09)70003-8 · 2009 · External reference
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax
10.1182/bloodadvances.2023011757 · 2024 · External reference
RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives
10.1038/s41408-024-01054-2 · 2024 · External reference
Impact of KRAS and NRAS mutations on outcomes in acute myeloid leukemia
10.1080/10428194.2023.2190432 · 2023 · External reference
Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML
10.1038/s41375-024-02175-0 · 2024 · External reference
Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission
10.1073/pnas.1324297111 · 2014 · External reference
Mathematical modeling and mutational analysis reveal optimal therapy to prevent malignant transformation in Grade II IDH-mutant gliomas
10.1158/0008-5472.can-21-0985 · 2021 · External reference
